{"id":"NCT02905266","sponsor":"Bristol-Myers Squibb","briefTitle":"A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma","officialTitle":"Phase IIIb, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Previously Untreated Unresectable or Metastatic Melanoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-10-27","primaryCompletion":"2017-10-23","completion":"2019-10-25","firstPosted":"2016-09-19","resultsPosted":"2019-01-08","lastUpdate":"2020-12-17"},"enrollment":106,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Melanoma"],"interventions":[{"type":"BIOLOGICAL","name":"Nivolumab","otherNames":[]},{"type":"BIOLOGICAL","name":"Ipilimumab","otherNames":[]}],"arms":[{"label":"Nivolumab and Ipilimumab Concomitant Administration","type":"EXPERIMENTAL"},{"label":"Nivolumab and Ipilimumab Sequential Administration","type":"EXPERIMENTAL"}],"summary":"This is a safety and efficacy study of different administration regimens of nivolumab plus Ipilimumab in subjects with previously untreated, unresectable or metastatic melanoma.","primaryOutcome":{"measure":"Percentage of Participants Affected by Adverse Events (AEs) in the Broad Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ)","timeFrame":"Within 2 days from administration of any of the 4 doses in part 1 period (approximately 12 weeks)","effectByArm":[{"arm":"Fixed Ratio Combination","deltaMin":15.1,"sd":null},{"arm":"Sequential Combination","deltaMin":17,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":16,"countries":["Australia","France","Italy","Spain"]},"refs":{"pmids":["40614118"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":53},"commonTop":["Diarrhoea","Asthenia","Pyrexia","Rash","Pruritus"]}}